PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr CLINDOXYL ADV Gel
clindamycin and benzoyl peroxide gel, 1% / 3%, w/w
(clindamycin as clindamycin phosphate)

Pr CLINDOXYL Gel
clindamycin and benzoyl peroxide gel, 1% / 5%, w/w
(clindamycin as clindamycin phosphate)

Topical Acne Therapy
Professed Standard

GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
www.stiefel.ca

Date of Revision:
November 2, 2018

Submission Control No: 215840

© 2018 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3
  SUMMARY PRODUCT INFORMATION ......................................................................... 3
  INDICATIONS AND CLINICAL USE .......................................................................... 3
  CONTRAINDICATIONS ............................................................................................... 4
  WARNINGS AND PRECAUTIONS .............................................................................. 4
  ADVERSE REACTIONS ............................................................................................. 7
  DRUG INTERACTIONS ............................................................................................. 9
  DOSAGE AND ADMINISTRATION ........................................................................... 10
  OVERDOSAGE ........................................................................................................ 10
  ACTION AND CLINICAL PHARMACOLOGY ............................................................ 11
  STORAGE AND STABILITY ..................................................................................... 12
  SPECIAL HANDLING INSTRUCTIONS .................................................................... 12
  DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 12

PART II: SCIENTIFIC INFORMATION ....................................................................... 14
  PHARMACEUTICAL INFORMATION ....................................................................... 14
  CLINICAL TRIALS .................................................................................................. 16
  MICROBIOLOGY ...................................................................................................... 20
  TOXICOLOGY .......................................................................................................... 20
  REFERENCES ........................................................................................................... 23

PATIENT MEDICATION INFORMATION .................................................................. 24
Pr CLINDOXYL ADV Gel

clindamycin and benzoyl peroxide gel, 1% / 3%, w/w

(clindamycin as clindamycin phosphate)

Pr CLINDOXYL Gel

clindamycin and benzoyl peroxide gel, 1% / 5%, w/w

(clindamycin as clindamycin phosphate)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Non-medicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical</td>
<td>Gel</td>
<td>None.</td>
</tr>
<tr>
<td></td>
<td>Clindamycin 1% and benzoyl peroxide 3%, w/w (clindamycin as clindamycin phosphate)</td>
<td>For a complete listing, see Dosage Forms, Composition and Packaging section.</td>
</tr>
<tr>
<td></td>
<td>Gel</td>
<td>Methylparaben.</td>
</tr>
<tr>
<td></td>
<td>Clindamycin 1% and benzoyl peroxide 5%, w/w (clindamycin as clindamycin phosphate)</td>
<td>For a complete listing, see Dosage Forms, Composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

CLINDOXYL ADV (1% clindamycin and 3% benzoyl peroxide) Gel and CLINDOXYL (1% clindamycin and 5% benzoyl peroxide) Gel are indicated in the topical treatment of moderate acne vulgaris characterized by the presence of comedones, papules and pustules.

CLINDOXYL ADV Gel and CLINDOXYL Gel are not indicated for the treatment of cystic acne.

CLINDOXYL ADV Gel and CLINDOXYL Gel contain an antibacterial ingredient, clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin, CLINDOXYL ADV Gel and CLINDOXYL Gel should only be used for the authorized indication and clinical use.
**Pediatrics (< 12 years of age):** Safety and efficacy of CLINDOXYL ADV Gel and CLINDOXYL Gel have not been established in patients under the age of 12 years.

**CONTRAINDICATIONS**

CLINDOXYL ADV (1% clindamycin and 3% benzoyl peroxide) Gel and CLINDOXYL (1% clindamycin and 5% benzoyl peroxide) Gel are contraindicated in:

- Patients who have a history of hypersensitivity to either of the active ingredients (clindamycin or benzoyl peroxide), or the excipients. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

- Patients who have a history of hypersensitivity to medicines containing lincomycin.

- Patients with, or with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis).

**WARNINGS AND PRECAUTIONS**

**General**

For external (dermatological) use only. Not for oral, ophthalmic or intravaginal use.

**Drug interactions:** Concomitant topical acne treatments are not recommended because a possible cumulative irritancy effect may occur, which sometimes may be severe, especially with peeling, desquamating, or abrasive agents. If severe irritation develops, discontinue use and institute appropriate therapy.

Use of clindamycin phosphate or benzoyl peroxide with other drugs may lead to drug-drug interactions (see DRUG INTERACTIONS, Drug-Drug Interactions).

**Benzoyl peroxide:** Avoid contact with hair, fabrics, carpeting or other materials, as CLINDOXYL ADV Gel or CLINDOXYL Gel may cause bleaching. As benzoyl peroxide may cause increased sensitivity to sunlight, sunlamps should not be used and deliberate or prolonged exposure to sunlight should be avoided or minimized. When exposure to strong sunlight cannot be avoided, patients should be advised to use a sunscreen product and wear protective clothing.

If a patient has sunburn, this should be resolved before using CLINDOXYL ADV Gel or CLINDOXYL Gel.
Clindamycin phosphate: Gram-negative folliculitis has been reported in association with the long term use of clindamycin. Should gram-negative folliculitis occur, discontinue use of CLINDOXYL ADV Gel or CLINDOXYL Gel, and institute appropriate therapy.

**Gastrointestinal**

*Clostridium difficile*-Associated Disease: Systemic absorption of clindamycin has been demonstrated following topical use of CLINDOXYL ADV Gel and CLINDOXYL Gel. *Clostridium difficile*-associated disease (CDAD) has been reported with the use of topical, oral and parenteral administration of clindamycin, including with the use of CLINDOXYL Gel (see ADVERSE REACTIONS). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic mega colon, or perforation of the colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur 2 months after the administration of antibacterial agents (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions).

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of *Clostridium difficile*. *Clostridium difficile* produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridium difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridium difficile*. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases.

**Ophthalmologic/Mucosal/Skin**

Benzoyl peroxide: Avoid contact with the mouth, eyes, lips, other mucous membranes or areas of irritated or broken skin. In the event of accidental contact with sensitive surfaces (eyes, abraded skin, mucous membranes), rinse with copious amounts of cool tap water. In addition, care should be taken when applying CLINDOXYL ADV Gel or CLINDOXYL Gel to the neck and other sensitive areas.

During the first weeks of treatment, patients may experience peeling and reddening. In these patients, these symptoms will normally subside if treatment is temporarily interrupted and restarted after symptoms have subsided. Depending upon the severity of these side effects, patients can use a moisturizer, temporarily reduce the frequency of application of CLINDOXYL ADV Gel / CLINDOXYL Gel or temporarily discontinue use; however, efficacy has not been established for less than once daily dosing frequencies.

If excessive dryness or peeling occurs, frequency of application should be reduced or
application temporarily interrupted.

If severe local irritation (e.g. severe erythema, severe dryness and itching, severe stinging/burning) develops, discontinue use of CLINDOXYL ADV Gel or CLINDOXYL Gel, and institute appropriate therapy.

Patients should be advised that excessive application of CLINDOXYL ADV Gel or CLINDOXYL Gel will not improve efficacy, but may increase the risk of skin irritation.

**Susceptibility/Resistance**

**Development of Drug Resistant Bacteria**

Prescribing CLINDOXYL ADV Gel or CLINDOXYL Gel in the absence of the authorized indication is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.

**Cross-resistance and resistance**

Cross-resistance has been demonstrated between clindamycin and lincomycin. Resistance to clindamycin is often associated with inducible resistance to erythromycin (see DRUG INTERACTIONS).

Benzoyl peroxide reduces the potential for emergence of organisms resistant to clindamycin. However, patients with a recent history of systemic or topical clindamycin or erythromycin use are more likely to have pre-existing anti-microbial resistant *Propionibacterium acnes* and commensal flora (see ACTION AND CLINICAL PHARMACOLOGY, Mechanism of Action and MICROBIOLOGY).

**Special Populations**

**Fertility:** There are no data on the effect of topical clindamycin or benzoyl peroxide on fertility in humans.

**Pregnant Women:** There are no well-controlled studies in pregnant women treated with topical CLINDOXYL ADV Gel or CLINDOXYL Gel. There are limited data on the use of topical clindamycin or benzoyl peroxide in pregnant women. CLINDOXYL ADV Gel or CLINDOXYL Gel should not be administered to a pregnant woman unless the expected benefits to the mother outweigh the potential risks to the fetus.

**Nursing Women:** Topical CLINDOXYL ADV Gel or CLINDOXYL Gel has not been studied during breast-feeding. It is not known whether benzoyl peroxide or clindamycin are excreted in human milk following the topical use of CLINDOXYL ADV Gel or CLINDOXYL Gel. Orally and parenterally administered clindamycin have been reported to appear in breast milk. CLINDOXYL ADV Gel or CLINDOXYL Gel should not be used during lactation unless the expected benefits to the mother outweigh the potential risks to the infant. If used during lactation, CLINDOXYL ADV Gel or CLINDOXYL Gel should not be applied to the chest so as to avoid accidental ingestion by the infant.
Pediatrics (<12 years of age): Safety and efficacy of CLINDOXYL ADV Gel and CLINDOXYL Gel in patients under the age of 12 have not been established.

Geriatrics (>65 years of age): Safety and efficacy of CLINDOXYL ADV Gel and CLINDOXYL Gel in patients over the age of 65 have not been established.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

CLINDOXYL ADV (1% clindamycin / 3% benzoyl peroxide) Gel: The number of subjects who experienced treatment-related adverse events was low and was similar in each treatment group. No individual treatment-related adverse event was reported by more than 2 subjects (≤ 1%) within any of the treatment groups. The most frequently-reported treatment-related adverse events were mild or moderate application site dermatitis and photosensitivity, with each occurring in 2 subjects (0.6%) in the CLINDOXYL ADV Gel group. One subject (0.3%) discontinued CLINDOXYL ADV Gel due to application site dermatitis.

CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel: Nine of the 113 adverse events were related to CLINDOXYL Gel. These adverse reactions were 1 case of mild application site paraesthesia, 1 case of acne worsening and 7 cases of mild to moderate pruritus and erythema, as well as dryness at the application site that lasted 3 to 48 days. There were no discontinuations due to adverse drug reactions with CLINDOXYL Gel.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

CLINDOXYL ADV (1% clindamycin / 3% benzoyl peroxide) Gel: In a controlled study where a total of 327 subjects (eligible subjects were between 12 and 45 years of age with mild-to-moderate acne vulgaris) applied CLINDOXYL ADV Gel once daily for 12 weeks, subjects were assessed for local cutaneous signs and symptoms of erythema, dryness, peeling, itching, and burning/stinging. The percentage of subjects that had symptoms present before treatment and present at week 12 are shown in Table 1 and Table 2.
Table 1  Percentage of Subjects Treated with CLINDOXYL ADV Gel with Symptoms of Local Skin Reactions – Burning/Stinging and Itching (N=327)

<table>
<thead>
<tr>
<th></th>
<th>Before Treatment (Baseline)</th>
<th>End of Treatment (Week 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Slight</td>
<td>Moderate</td>
</tr>
<tr>
<td>Burning/Stinging</td>
<td>15%</td>
<td>4%</td>
</tr>
<tr>
<td>Itching</td>
<td>28%</td>
<td>6%</td>
</tr>
</tbody>
</table>

Table 2  Percentage of Subjects Treated with CLINDOXYL ADV Gel with Symptoms of Local Skin Reactions - Dryness, Erythema, and Peeling (N=327)

<table>
<thead>
<tr>
<th></th>
<th>Before Treatment (Baseline)</th>
<th>End of Treatment (Week 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Slight</td>
<td>Mild</td>
</tr>
<tr>
<td>Dryness</td>
<td>15%</td>
<td>2%</td>
</tr>
<tr>
<td>Erythema</td>
<td>19%</td>
<td>11%</td>
</tr>
<tr>
<td>Peeling</td>
<td>10%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Table 3 shows the most frequent adverse drug reactions determined by the investigator to be possibly, probably, or definitely treatment-related and reported in ≥1% subjects in the CLINDOXYL ADV Gel or comparator groups. No other adverse drug reactions (<1%) were reported for CLINDOXYL ADV Gel.

Table 3  Most Frequent Adverse Drug Reactions Reported in ≥1% of Subjects in the CLINDOXYL ADV Gel or Comparator Groups

<table>
<thead>
<tr>
<th>System Organ Class (Preferred Term)</th>
<th>CLINDOXYL ADV Gel (N=327)</th>
<th>Clindamycin 1% Gel (N=328)</th>
<th>Benzoyl Peroxide 3% Gel (N=328)</th>
<th>Vehicle Gel (N=332)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Disorders and Administration Site Conditions, n (%)</td>
<td>2 (1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Application site dermatitis</td>
<td>0</td>
<td>0</td>
<td>2 (1)</td>
<td>0</td>
</tr>
<tr>
<td>Application site irritation</td>
<td>2 (1)</td>
<td>1 (&lt;1)</td>
<td>1 (&lt;1)</td>
<td>2 (1)</td>
</tr>
</tbody>
</table>

CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel: In controlled clinical trials where a total of 172 subjects received CLINDOXYL Gel, the reported adverse events considered to have a relationship to CLINDOXYL Gel were comprised mainly of reactions at the site of application such as peeling (16.3%), erythema (7.6%), dryness (7%), burning (2.3%) and pruritus (1.7%). Mild paraesthesia and worsening of acne were noted in one subject each.

Post-Market Adverse Drug Reactions

*Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.*
**Gastrointestinal disorders:** Diarrhea, abdominal pain, bloody diarrhea, colitis (including pseudomembranous colitis). (See WARNINGS AND PRECAUTIONS, *Clostridium difficile*-Associated Disease)

**General disorders and administration site conditions:** Application site reactions including discoloration.

**Immune system disorders:** Anaphylaxis, as well as allergic reactions leading to hospitalization, application site hypersensitivity such as urticaria, application site swelling and swelling of the face and tongue including angioedema.

### DRUG INTERACTIONS

#### Drug-Drug Interactions

**Table 4 **Established or Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Drug</th>
<th>Ref</th>
<th>Effect</th>
<th>Clinical comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuromuscular blocking agents</td>
<td>CT</td>
<td>Clindamycin has been shown to have neuromuscular blocking properties that may enhance action of other neuromuscular blocking agents.</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>In vitro</td>
<td>Clindamycin and erythromycin have been shown to be antagonists.</td>
<td>Should not be used concomitantly.</td>
</tr>
<tr>
<td>Tretinoin, isotretinoin, tazarotene</td>
<td>In vitro</td>
<td>Concomitant application of CLINDOXYL ADV Gel or CLINDOXYL Gel with tretinoin, isotretinoin and tazarotene should be avoided since benzoyl peroxide may reduce their efficacy and may increase irritation.</td>
<td>If combination treatment is required, the products should be applied at different times of the day (e.g., one in the morning and the other in the evening).</td>
</tr>
<tr>
<td>Concomitant topical acne medication (to treat both inflammatory and non-inflammatory lesions)</td>
<td>CT</td>
<td>Possible cumulative irritancy may occur, which sometimes may be severe, especially with the use of peeling, desquamating or abrasive agents.</td>
<td>If severe irritation or dermatitis develops, discontinue use and institute appropriate therapy.</td>
</tr>
<tr>
<td>Topical sulphonamides</td>
<td>CT</td>
<td>When the use of topical benzoyl peroxide-containing preparation is followed by topical sulphonamide-containing products, this may cause skin and facial hair to temporarily change colour (yellow / orange).</td>
<td>Avoid concomitant use.</td>
</tr>
</tbody>
</table>

CT = Clinical Trial

#### Drug-Food Interactions

Interactions with food have not been established.
**Drug-Herb Interactions**

Interactions with herbal products have not been established.

**Drug-Laboratory Interactions**

Interactions with laboratory tests have not been established.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

For external (dermatological) use only. Not for oral, ophthalmic or intravaginal use.

**Recommended Dose and Administration**

The skin should be thoroughly washed with a mild, non-irritating cleanser, rinsed with warm water and gently patted dry.

Once daily, gently apply CLINDOXYL ADV (1% clindamycin and 3% benzoyl peroxide) Gel or CLINDOXYL (1% clindamycin and 5% benzoyl peroxide) Gel to lightly cover the entire affected areas of the face with a thin layer of gel. A pea-sized amount should be applied for each area of the face (e.g., forehead, chin, each cheek).

Hands should be washed with soap and water after application of CLINDOXYL ADV Gel or CLINDOXYL Gel.

**Patients with Renal Impairment**

No dosage adjustment is necessary. As percutaneous absorption is low following topical application, renal impairment is not expected to result in systemic exposure of clinical significance.

**Patients with Hepatic Impairment**

No dosage adjustment is necessary. As percutaneous absorption is low following topical application, hepatic impairment is not expected to result in systemic exposure of clinical significance.

**Missed Dose**

If patients forget to apply CLINDOXYL ADV Gel or CLINDOXYL Gel, they should be instructed to apply the next dose at the usual time. Patients should be instructed not to apply a double dose to make up for forgotten doses.

**OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre.
**Symptoms**

Topically applied benzoyl peroxide is not generally absorbed in sufficient amounts to produce systemic effects. Excessive application of topically applied clindamycin phosphate formulations can be absorbed in sufficient amounts to produce systemic effects (see WARNINGS AND PRECAUTIONS).

Excessive topical application of CLINDOXYL ADV Gel or CLINDOXYL Gel may cause severe skin irritation from the benzoyl peroxide and gastrointestinal side effects, including abdominal pain, nausea, vomiting and diarrhea, due to systemic absorption of clindamycin phosphate from CLINDOXYL ADV Gel or CLINDOXYL Gel.

In the event of accidental ingestion of CLINDOXYL ADV Gel or CLINDOXYL Gel, the same gastrointestinal side effects as those expected with oral clindamycin are expected (see WARNINGS AND PRECAUTIONS).

**Treatment**

In the case of symptoms resulting from excessive topical application of CLINDOXYL ADV Gel or CLINDOXYL Gel, it should be discontinued until the skin has recovered before resuming therapy (see WARNINGS AND PRECAUTIONS).

Appropriate symptomatic measures (e.g., cold compresses) should be taken to provide relief from irritation due to excessive topical application. Further management of excessive topical application or accidental ingestion should be as clinically indicated or as recommended by the regional Poison Control Centre or healthcare professional, where available.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

**Clindamycin Phosphate:** Clindamycin phosphate is a semi-synthetic antibiotic which is derived from the parent antibiotic, lincomycin. Although clindamycin phosphate is inactive *in vitro*, rapid *in vivo* hydrolysis converts this compound to the active antibiotic clindamycin. Like other macrolides, clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of ribosomes. Clindamycin *in vitro* inhibits *Propionibacterium acnes*, an organism that has been associated with acne vulgaris. Clindamycin also reduces inflammation by inhibiting leukocyte chemotaxis.

**Benzoyl Peroxide:** The effectiveness of benzoyl peroxide in the treatment of acne vulgaris is primarily attributable to its bactericidal activity, especially with respect to *Propionibacterium acnes*, the predominant organism in sebaceous follicles and comedones. The antibacterial activity of this compound is presumably due to the release of active or free-radical oxygen capable of oxidizing bacterial proteins. This action, combined with a mild keratolytic effect, is believed to be responsible for its usefulness in acne. *P. acnes* resistance has not been reported with benzoyl peroxide. In acne patients treated topically with benzoyl peroxide, resolution of the acne usually coincides with the
reduction in the level of *P. acnes* and free fatty acids.

**Pharmacodynamics**

Clinical studies in humans have demonstrated that CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel did not have detectable phototoxic potential or photocontact allergenic potential in human skin. CLINDOXYL Gel was found to possess an insignificant primary irritant potential. No instance of delayed contact sensitization was reported.

**Pharmacokinetics**

**CLINDOXYL ADV (1% clindamycin / 3% benzoyl peroxide) Gel:** In an open-label study (24 patients with moderate-to-severe acne vulgaris in each treatment arm), topical administration of approximately 4 grams of CLINDOXYL ADV Gel under maximal-use conditions once daily for 5 days, resulted in systemic clindamycin concentrations that were quantifiable in all 24 patients in each treatment arm starting from 1 hour post dose. Clindamycin was slowly absorbed after topical application, reaching maximal observed plasma concentrations within 6 hours. All plasma clindamycin concentrations were ≤ 5.1 ng/mL on Day 5.

**Benzoyl Peroxide:** Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid. Less than 5% of the dose enters the systemic circulation as benzoic acid.

**STORAGE AND STABILITY**

Prior to Dispensing: Store between 2° and 8°C. Do not freeze.

**SPECIAL HANDLING INSTRUCTIONS**

To the Pharmacist:

**CLINDOXYL ADV (1% clindamycin / 3% benzoyl peroxide) Gel:**

Dispense with a 60 day expiration date and specify “Store at room temperature (15° - 25°C). Do not freeze. Keep tube tightly closed. Keep out of the reach of children”.

**CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel:**

Dispense with a 60 day expiration date and specify “Store at room temperature (15° - 25°C). Do not freeze. Keep tube tightly closed. Keep out of the reach of children”.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

**CLINDOXYL ADV (1% clindamycin / 3% benzoyl peroxide) Gel:**
Available in a 45 g tube.

Each gram of CLINDOXYL ADV Gel contains 1% clindamycin (clindamycin as clindamycin phosphate) equivalent to 10 mg clindamycin in combination with 3% (30 mg) benzoyl peroxide in a base consisting of carbomer homopolymer, dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, silicon dioxide, poloxamer, purified water and sodium hydroxide.

**CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel:**

Available in a 45 g tube.

Each gram of CLINDOXYL Gel contains 1% clindamycin (clindamycin as clindamycin phosphate) equivalent to 10 mg clindamycin in combination with 5% (50 mg) benzoyl peroxide in a base consisting of carbomer homopolymer, dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, silicon dioxide, methylparaben, poloxamer, purified water and sodium hydroxide.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance - Clindamycin Phosphate

Proper name: Clindamycin Phosphate

Chemical name: Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinocarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate)

Molecular formula: $\text{C}_{18}\text{H}_{34}\text{ClN}_{2}\text{O}_{8}\text{PS}$

Molecular mass: 504.97

Structural formula:

Physicochemical properties: Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. It occurs as a white to off-white, hygroscopic, crystalline powder. It is freely soluble in water, slightly soluble in dehydrated alcohol, very slightly soluble in acetone and practically odourless and has a bitter taste.
Drug Substance - Benzoyl Peroxide

Proper name: Benzoyl Peroxide

Chemical name: Dibenzoyl peroxide

Molecular formula: $\text{C}_{14}\text{H}_{10}\text{O}_4$

Molecular mass: 242.2

Structural formula:

![Structural formula of Benzoyl Peroxide]

Physicochemical properties: Benzoyl peroxide is a white amorphous or granular powder. It loses water rapidly on exposure to air. Benzoyl peroxide is sparingly soluble in water or alcohol; soluble in benzene, chloroform and ether.
CLINICAL TRIALS

Pivotal Clinical Study

CLINDOXYL ADV (1% clindamycin / 3% benzoyl peroxide) Gel:

Study Demographics and Trial Design:

Table 5  Summary of Study Design and Demographics

<table>
<thead>
<tr>
<th>Study No.</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (N = number)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>W0261-301 (Reference 4)</td>
<td>Multi-centre, blinded, randomized 1:1:1:1 to each study group where CLINDOXYL ADV Gel was compared to clindamycin in vehicle gel, benzoyl peroxide in vehicle gel, and vehicle gel alone</td>
<td>Once-daily topical administration (facial area) for 12 weeks</td>
<td>N = 1,315 subjects with acne vulgaris (79% were Caucasian)</td>
<td>20.4 (12 – 45 years old)</td>
<td>60% were females</td>
</tr>
</tbody>
</table>

Acne severity was evaluated using lesion counts and the 6-point Investigator’s Global Assessment (IGA) scale. The IGA scoring scale used in the clinical trial for CLINDOXYL ADV Gel is as shown in Table 6.

Table 6  Investigator Global Assessment (IGA) Scale

<table>
<thead>
<tr>
<th></th>
<th>Clear</th>
<th>Almost Clear</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Very Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Clear</td>
<td>Clear skin with no inflammatory or non-inflammatory lesions.</td>
<td>Rare non-inflammatory lesions with no more than rare papules.</td>
<td>Greater than grade 1, some non-inflammatory lesions, with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions).</td>
<td>Greater than grade 2, up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion.</td>
<td>Greater than grade 3, up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions.</td>
</tr>
</tbody>
</table>

At baseline, the mean number of acne lesions per subject was 72 total lesions, with 45.3 non-inflammatory lesions and 26.6 inflammatory lesions. The majority of subjects (62%) enrolled with a baseline IGA score of 3 (range 2 to 4).
Study Results:

CLINDOXYL ADV Gel was more effective than clindamycin and vehicle alone in reducing the number of inflammatory, non-inflammatory, and total acne lesions. CLINDOXYL ADV Gel was more effective than benzoyl peroxide in reducing the number of inflammatory and total acne lesions. CLINDOXYL ADV Gel was more effective in decreasing the IGA of acne severity at Week 12, as measured by the proportion of subjects who had a 2 grade improvement from baseline in IGA and the proportion of subjects who had clear or almost clear skin. The efficacy results from baseline to Week 12 are summarized in Table 7.

Table 7  Outcomes for Primary and Key Secondary Endpoints (ITT Population)

<table>
<thead>
<tr>
<th>Week 12</th>
<th>CLINDOXYL ADV Gel (N=327)</th>
<th>Clindamycin 1% Gel (N=328)</th>
<th>Benzoyl Peroxide 3% Gel (N=328)</th>
<th>Vehicle Gel (N=332)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammatory Lesions</strong>&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean absolute reduction&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.2</td>
<td>15.6 (p&lt;0.001)</td>
<td>16.8 (p=0.015)</td>
<td>13.1 (p&lt;0.001)</td>
</tr>
<tr>
<td>Mean percentage reduction&lt;sup&gt;b&lt;/sup&gt;</td>
<td>68.9%</td>
<td>58.1% (p&lt;0.001)</td>
<td>61.8% (p=0.005)</td>
<td>48.8% (p&lt;0.001)</td>
</tr>
<tr>
<td><strong>Non-inflammatory Lesions</strong>&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean absolute reduction&lt;sup&gt;a&lt;/sup&gt;</td>
<td>24.8</td>
<td>19.8 (p&lt;0.001)</td>
<td>22.2 (p=0.102)</td>
<td>14.8 (p&lt;0.001)</td>
</tr>
<tr>
<td>Mean percentage reduction&lt;sup&gt;b&lt;/sup&gt;</td>
<td>53.9%</td>
<td>43.3% (p&lt;0.001)</td>
<td>50.8% (p=0.199)</td>
<td>34.0% (p&lt;0.001)</td>
</tr>
<tr>
<td><strong>Total Lesions</strong>&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean absolute reduction&lt;sup&gt;a&lt;/sup&gt;</td>
<td>43.0</td>
<td>35.5 (p&lt;0.001)</td>
<td>39.0 (p=0.032)</td>
<td>27.8 (p&lt;0.001)</td>
</tr>
<tr>
<td>Mean percentage reduction&lt;sup&gt;b&lt;/sup&gt;</td>
<td>59.8%</td>
<td>49.2% (p&lt;0.001)</td>
<td>55.5% (p=0.077)</td>
<td>40.4% (p&lt;0.001)</td>
</tr>
<tr>
<td><strong>Investigator’s Global Assessment</strong>&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage of subjects with minimum 2-grade improvement in IGA from baseline to Week 12&lt;sup&gt;a&lt;/sup&gt;</td>
<td>39%</td>
<td>25% (p&lt;0.001)</td>
<td>30% (p=0.016)</td>
<td>18% (p&lt;0.001)</td>
</tr>
<tr>
<td>Percentage of subjects with IGA of clear or almost clear skin at Week 12&lt;sup&gt;b&lt;/sup&gt;</td>
<td>45%</td>
<td>28% (p&lt;0.001)</td>
<td>35% (p=0.008)</td>
<td>24% (p&lt;0.001)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Primary endpoints. <sup>b</sup>Secondary endpoints. <sup>c</sup>P-values based on an analysis of covariance (ANCOVA) with factors of treatment, center, and treatment-by-center interaction. If the treatment-by-center interaction was not significant at the 0.1 level, this interaction was excluded from the model. <sup>d</sup>P-values based on Cochran-Mantel-Haenszel test stratified by center. Subjects with missing week 12 evaluations were considered failures. Breslow-Day test exceeded the 0.1 significance level, indicating consistency of the results across investigational centers.
CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel:

In three double-blind clinical studies with a total of 673 patients, 188 patients were randomized to CLINDOXYL Gel, benzoyl peroxide and clindamycin, respectively, in addition to 109 patients randomized to vehicle. CLINDOXYL Gel applied once daily for 11 weeks was significantly more effective than vehicle, benzoyl peroxide, and clindamycin in the treatment of inflammatory lesions of moderate to moderately severe facial acne vulgaris in two of the three studies (Studies 1 and 2). CLINDOXYL Gel group showed greater overall improvement in the investigator’s global assessment than the benzoyl peroxide, clindamycin and vehicle groups in two of the three studies (Studies 1 and 2). Patients were instructed to wash and dry the face, and then apply medication to the entire face, once daily, in the evening before retiring. Patients were evaluated and acne lesions counted at each clinical visit: weeks 2, 5, 8, 11. The primary efficacy measures were the lesion counts and the investigator’s global assessment evaluated at week 11. Percent reductions in non-inflammatory lesion counts, inflammatory lesion counts, total inflammatory lesion counts and global improvement scores after treatment for 11 weeks in these three studies are shown in Table 8.

Table 8  Outcomes for Primary Endpoints (Preferred Data Set1)

<table>
<thead>
<tr>
<th>Week 11</th>
<th>Study 1 (n=108)</th>
<th>Study 2 (n=226)</th>
<th>Study 3 (n=250)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-inflammatory Lesion Counts*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLINDOXYL Gel</td>
<td>26.5</td>
<td>40.4</td>
<td>25.7</td>
</tr>
<tr>
<td>Clindamycin 1% Gel</td>
<td>-5.2 (p=0.007)</td>
<td>15.3 (p=0.003)</td>
<td>11.2 (p&lt;0.001)</td>
</tr>
<tr>
<td>Benzoyl Peroxide 5% Gel</td>
<td>14.2 (p=0.309)</td>
<td>34.9 (p=0.456)</td>
<td>18.8 (p=0.091)</td>
</tr>
<tr>
<td>Vehicle Gel</td>
<td>-12.6 (p=0.001)</td>
<td>-9.6 (p&lt;0.001)</td>
<td>15.4 (p=0.037)</td>
</tr>
<tr>
<td>Week 11</td>
<td>Mean Percent Reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 1 (n=108)</td>
<td>Study 2 (n=226)</td>
<td>Study 3 (n=250)</td>
</tr>
<tr>
<td><strong>Inflammatory Lesion Counts</strong>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLINDOXYL Gel</td>
<td>66.5</td>
<td>58.4</td>
<td>43.4</td>
</tr>
<tr>
<td>Clindamycin 1% Gel</td>
<td>34.5 (p=0.010)</td>
<td>35.9 (p&lt;0.001)</td>
<td>39.8 (p=0.517)</td>
</tr>
<tr>
<td>Benzoyl Peroxide 5% Gel</td>
<td>39.5 (p=0.037)</td>
<td>39.4 (p=0.003)</td>
<td>33.5 (p=0.107)</td>
</tr>
<tr>
<td>Vehicle Gel</td>
<td>18.2 (p&lt;0.001)</td>
<td>-7.6 (p&lt;0.001)</td>
<td>28.6 (p=0.051)</td>
</tr>
<tr>
<td><strong>Total Lesion Counts</strong>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLINDOXYL Gel</td>
<td>41.5</td>
<td>47.7</td>
<td>32.5</td>
</tr>
<tr>
<td>Clindamycin 1% Gel</td>
<td>10.4 (p=0.003)</td>
<td>26.5 (p=0.001)</td>
<td>23.5 (p=0.021)</td>
</tr>
<tr>
<td>Benzoyl Peroxide 5% Gel</td>
<td>21.9 (p=0.066)</td>
<td>38.3 (p=0.097)</td>
<td>25.5 (p=0.076)</td>
</tr>
<tr>
<td>Vehicle Gel</td>
<td>-1.4 (p&lt;0.001)</td>
<td>-6.0 (p&lt;0.001)</td>
<td>20.6 (p=0.015)</td>
</tr>
<tr>
<td><strong>Percentage of patients with Good to Excellent Global Improvement</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLINDOXYL Gel</td>
<td>75.0</td>
<td>62.7</td>
<td>31.5</td>
</tr>
<tr>
<td>Clindamycin 1% Gel</td>
<td>37.9 (p=0.010)</td>
<td>35.0 (p=0.002)</td>
<td>44.3 (p=0.197)</td>
</tr>
<tr>
<td>Benzoyl Peroxide 5% Gel</td>
<td>41.7 (p=0.030)</td>
<td>41.2 (p=0.013)</td>
<td>32.9 (p=0.745)</td>
</tr>
<tr>
<td>Vehicle Gel</td>
<td>14.8 (p&lt;0.001)</td>
<td>6.5 (p&lt;0.001)</td>
<td>35.1 (p=0.577)</td>
</tr>
</tbody>
</table>

1 Only patients completing the study and compliant with the protocol were considered valid, and their data were included in the preferred data set.

* Comparisons between treatments and CLINDOXYL Gel: p-values were calculated using one-way analysis of variance with treatment as the effect.

**Global improvement was defined on a scale of 0 to 4; 0 = worsening, 1 = poor, 2 = fair, 3 = good and 4 = excellent.
Defined as dichotomous variable Success (global improvement scores of 3 or 4) or Failure (scores of 0, 1 or 2).
Comparisons between treatments and CLINDOXYL Gel: p-values were calculated using logistic regression with treatment as the effect.
MICROBIOLOGY

No microbiology studies were conducted in the clinical trials with CLINDOXYL ADV Gel or CLINDOXYL Gel.

Clindamycin and benzoyl peroxide individually have been shown to have in vitro activity against Propionibacterium acnes, an organism which has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes is not known and was not examined in clinical trials with CLINDOXYL ADV Gel or CLINDOXYL Gel.

Bacterial resistance may develop to macrolides, such as clindamycin, especially when used alone. Resistance to clindamycin is often associated with resistance to erythromycin and lincomycin. The use of clindamycin may be associated with the overgrowth of antibiotic-resistant organisms (e.g., Propionibacterium acnes, Staphylococcus aureus, Streptococcus pyogenes). However, the inclusion of benzoyl peroxide in the CLINDOXYL ADV Gel or CLINDOXYL Gel has been shown to reduce the potential for emergence of organisms resistant to clindamycin.

TOXICOLOGY

Acute Animal Toxicity

No single-dose toxicity studies were conducted with CLINDOXYL ADV Gel or CLINDOXYL Gel.

CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel: The ocular irritation index of CLINDOXYL Gel was evaluated in rabbits. Evaluation of the cornea and of the iris showed no positive reactions following a single application (100 mg) of CLINDOXYL Gel. No edema or suppuration of the conjunctiva was reported. Minor erythema of the conjunctiva lasting for a maximum of 24 hours was reported in one animal. With respect to possible ocular irritation, CLINDOXYL Gel is considered very slightly irritant.

Chronic Animal Toxicity

CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel: Chronic toxicity of CLINDOXYL Gel has been studied in rats and minipigs. Results from these studies are summarized in Table 9.
### Table 9  Chronic toxicity of CLINDOXYL Gel

<table>
<thead>
<tr>
<th>Species</th>
<th>Treatment</th>
<th>Route</th>
<th>Length</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat (Sprague-Dawley)</td>
<td>CLINDOXYL Gel 80, 400, 2000 mg/kg/day; Vehicle gel 2000 mg/kg/day</td>
<td>Topical; 6 hours occluded exposure/day</td>
<td>28 days</td>
<td>No clinical signs observed, no effect on body weight change or food consumption; compared to controls, average weekly erythema score was increased for high dose females, low dose males showed increase in neutrophils and decrease in lymphocytes, mid dose females had fewer platelets, serum glucose levels were elevated for low and mid dose females, serum AST was elevated for mid dose males, no effect on necropsy, organ weights, relative organ weights, or histopathology; one accidental death in the control group on Day 1.</td>
</tr>
<tr>
<td>Minipig</td>
<td>CLINDOXYL Gel* 50, 500 mg/kg/day; non-aged CLINDOXYL Gel 500 mg/kg/day; Vehicle gel 500 mg/kg/day</td>
<td>Topical; 6 hours nonoccluded exposure/day</td>
<td>90 days</td>
<td>No treatment related findings were found at terminal sacrifice for any dose group. Application of CLINDOXYL Gel or its vehicle had no effect upon absolute organ weights, relative organ to body weight ratios or relative organ to brain ratios for any dose groups. Only a few gross lesions were observed in this study, and all were interpreted as incidental findings. No treatment related changes noted upon histopathological evaluation in any tissues.</td>
</tr>
</tbody>
</table>

* Aged at room temperature for 60 days and subsequently kept at 2°C to 8°C until application.

### Mutagenicity and Carcinogenicity

No genotoxicity or mutagenicity studies have been carried out with CLINDOXYL ADV Gel or CLINDOXYL Gel.

**Clindamycin phosphate:** Clindamycin phosphate was not genotoxic in the Ames Assay or in a rat micronucleus test.

**Benzoyl peroxide:** Numerous *in vitro* studies and an *in vivo* genotoxicity study of benzoyl peroxide have been conducted and reported in the published literature. While a few *in vitro* studies have suggested that benzoyl peroxide may be a weak mutagen, the overall genotoxicity profile does not indicate a significant biological relevance.

Benzoyl peroxide has been found to be inactive as a mutagen in the Ames Assay and other assays, including the mouse dominant lethal assay.
CLINDOXYL (1% clindamycin / 5% benzoyl peroxide) Gel: In a 2-year study in mice, topical administration of CLINDOXYL Gel at dose levels up to 8000 mg/kg/day (24000 mg/m²/day) showed no evidence of increased carcinogenic risk. A 52-week photocarcinogenicity study in which hairless mice were exposed to UV radiation and CLINDOXYL Gel at dose levels up to 2500 mg/kg/day (7500 mg/m²/day), demonstrated a slight reduction in the median time to onset of tumours when compared to UV radiation alone.

Reproductive and Developmental Toxicity

Teratological studies were not conducted with CLINDOXYL ADV Gel or CLINDOXYL Gel.

Clindamycin Phosphate: Reproductive studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin ranging from 100 to 600 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to clindamycin.

Subcutaneous injections of clindamycin phosphate at 100 and 180 mg/kg/day (aqueous solution) on Gestation Days 6 through 15 in ICR and CF-1 mice and Sprague Dawley rats had no detrimental effects on the litter weight, number of live and dead pups per litter and the number of resorptions per litter. Fetuses of rats and CF-1 mice showed no sign of teratogenic activity as evidenced by examination for gross external, visceral and skeletal malformations. In fetus of ICR mice, a low incidence of cleft palate was observed. The incidence of cleft palate in the clindamycin phosphate treated litter was not significantly different from the incidence reported in the control litter.

Benzoyl peroxide: In a combined repeat dose and reproduction/development toxicity study, benzoyl peroxide (250, 500, or 1000 mg/kg/day) was administered orally to male rats for 29 days and female rats for 41-51 days. There were no treatment-related changes observed in the mating period, mating rate, conception rate, delivery rate, birth rate, pregnancy period, luteinization number, implantation number and the rate of losing embryos and fetuses after implantation. In pups, body weight was significantly decreased in the high-dose group. Minor abnormalities were more than tripled in the 1000mg/kg/day group in comparison with the other study groups. The no-observed-adverse-effect level for reproductive toxicities was considered to be 500 mg/kg/day.
REFERENCES


READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

CLINDOXYL ADV Gel
clindamycin and benzoyl peroxide gel

CLINDOXYL Gel
clindamycin and benzoyl peroxide gel

Read this carefully before you start taking CLINDOXYL ADV Gel / CLINDOXYL Gel and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about CLINDOXYL ADV Gel / CLINDOXYL Gel.

What is CLINDOXYL ADV Gel / CLINDOXYL Gel used for?

CLINDOXYL ADV Gel / CLINDOXYL Gel is used on the skin to treat moderate acne. It should not be used to treat severe (cystic) acne.

CLINDOXYL ADV Gel / CLINDOXYL Gel contains an antibacterial ingredient called clindamycin that treats only bacterial infections. Clindamycin does not treat viral infections.

It is not known if CLINDOXYL ADV Gel / CLINDOXYL Gel are safe and effective in people under the age of 12 years old and over the age of 65 years old.

How does CLINDOXYL ADV Gel / CLINDOXYL Gel work?

CLINDOXYL ADV Gel / CLINDOXYL Gel works by:
- slowing or stopping the growth of acne bacteria.
- killing acne bacteria.

What are the ingredients in CLINDOXYL ADV Gel / CLINDOXYL Gel?

Medicinal ingredients in CLINDOXYL ADV Gel / CLINDOXYL Gel: clindamycin phosphate and benzoyl peroxide.

Non-medicinal ingredients in CLINDOXYL ADV Gel: carbomer homopolymer, dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, poloxamer, purified water, silicon dioxide and sodium hydroxide.

Non-medicinal ingredients in CLINDOXYL Gel: carbomer homopolymer, dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, methylparaben, poloxamer, purified water, silicon dioxide and sodium hydroxide.
CLINDOXYL ADV Gel / CLINDOXYL Gel comes in the following dosage forms:

CLINDOXYL ADV (1% clindamycin phosphate / 3% benzoyl peroxide) Topical Gel.

CLINDOXYL (1% clindamycin phosphate / 5% benzoyl peroxide) Topical Gel.

Do not use CLINDOXYL ADV Gel / CLINDOXYL Gel if:

You are allergic to:
- clindamycin.
- benzoyl peroxide.
- lincomycin, an antibiotic.
- any of the other ingredients in CLINDOXYL ADV Gel / CLINDOXYL Gel. See What are the ingredients in CLINDOXYL ADV Gel / CLINDOXYL Gel?

You have or have had the following:
- inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis.
- bloody, severe, or long-lasting diarrhea after using antibiotics.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take CLINDOXYL ADV Gel / CLINDOXYL Gel. Talk about any health conditions or problems you may have, including if you are:

- pregnant or planning to become pregnant.
- breast-feeding or planning to breast-feed.

If you do breast-feed:
- Do not apply to the chest or breast area to prevent the infant from ingesting CLINDOXYL ADV Gel / CLINDOXYL Gel.

Other warnings you should know about:

- CLINDOXYL ADV Gel / CLINDOXYL Gel is for external use only.
- Keep CLINDOXYL ADV Gel / CLINDOXYL Gel away from:
  - your eyes.
  - inside your nose.
  - your mouth and lips.
  - other mucous membranes, like inside your vagina.
  - areas of broken or irritated skin.
  - sunburned skin, until it has healed
- If contact occurs with any of the above areas, flush with water for at least 5 minutes. If discomfort continues, talk to your healthcare professional.
- Do not apply too much. Applying too much may cause skin irritation. If this happens, use the gel less often.
- Limit your time in the sun. If you have to be in the sun, wear protective clothing and sunscreen. Do not use sunlamps or tanning beds.
- Do not use other acne medications applied to the skin unless your healthcare professional tells you to do so.
- If you have recently used other medicines with clindamycin or erythromycin, CLINDOXYL ADV Gel / CLINDOXYL Gel may not work as well as it should. Tell your healthcare professional if you have recently used these other medicines.
Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with CLINDOXYL ADV Gel / CLINDOXYL Gel:

- Medicines used to relax muscles during surgery.
- Erythromycin, an antibiotic.
- Medicines applied to the skin that contain tretinoin, isotretonoin or tazarotene.
- Medicines called sulphonamides that are applied to the skin such as dapsone or sulacetamide.
- Other acne medications applied to the skin.

How to take CLINDOXYL ADV Gel / CLINDOXYL Gel:

- Before you apply:
  - wash your skin with a mild cleanser that doesn’t irritate your skin.
  - rinse with warm water.
  - gently pat dry.
- Apply only to your skin.
- After you apply:
  - wash your hands with soap and water.
- Although you may feel better early in treatment, use only as directed by your healthcare professional.
- Misuse or overuse of CLINDOXYL ADV Gel / CLINDOXYL Gel could lead to the growth of bacteria that will not be killed by clindamycin (resistance). This means that CLINDOXYL ADV Gel / CLINDOXYL Gel may not work for you in the future.
- Do not share your medicine.

Usual dose:

- Apply a thin layer to the affected area, once a day.
- For the face, apply a pea-sized amount for each affected area of your face, for example, to:
  - your chin.
  - each cheek.
  - your forehead.

Overdose:

If you accidently swallow CLINDOXYL ADV Gel / CLINDOXYL Gel seek medical advice.

If you think you have taken too much CLINDOXYL ADV Gel / CLINDOXYL Gel, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed dose:

If you missed a dose of this medication, apply it as soon as you remember. Do not apply two doses at the same time.
What are possible side effects from using CLINDOXYL ADV Gel / CLINDOXYL Gel?

These are not all the possible side effects you may feel when taking CLINDOXYL ADV Gel / CLINDOXYL Gel. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:
- skin rash that is red or bumpy.
- dry or itchy skin.
- numbness or tingling of the skin.
- burning or stinging of the skin.
- peeling skin.
- a change in colour of the skin where the medicine was applied.
- sensitivity to the sun.
- worsening of acne.

### Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom / effect</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>RARE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colitis (inflammation of the intestines):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• cramps.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• severe pain.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• bloating.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• severe or long lasting diarrhea (bloody or watery).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• nausea.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• vomiting.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folliculitis (an infection of your hair follicles):</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>• tiny red or white bump at the base of a hair.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• painful or tender skin.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• blisters.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• skin itching.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe allergic reaction:</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>• raised and itchy rash (hives).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• swelling of the mouth, face or tongue, making it hard to breathe.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• collapsing.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.
Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature (15° - 25°C). Do not freeze. Keep tube tightly closed.

Keep out of reach and sight of children.

If there is any CLINDOXYL ADV Gel / CLINDOXYL Gel left 60 days after you receive it, you should throw it out and talk to your healthcare professional.

If you want more information about CLINDOXYL ADV Gel / CLINDOXYL Gel:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (http://hc-sc.gc.ca/index-eng.php); the manufacturer’s website www.gsk.ca, or by calling 1-800-387-7374.

This leaflet was prepared by GlaxoSmithKline Inc.

Last Revised Nov-02-2018

© 2018 GSK group of companies or its licensor
Trademarks are owned by or licensed to the GSK group of companies